AC Immune CFO files initial share holdings

AC Immune SA’s Chief Financial Officer Christopher James Roberts has filed an initial statement of holdings.

Rhea-AI Filing Summary

AC Immune SA’s Chief Financial Officer Christopher James Roberts has filed an initial statement of holdings. He reports direct ownership of 155,382 common shares, which the footnotes state includes 109,564 common shares underlying outstanding restricted share units. He also reports a series of share options to buy common shares with exercise prices ranging from 2.32 to 6.88 and expirations between 2029 and 2035. One option grant is fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026.

Insider Trade Summary

9 transactions reported

Mixed 9 txns

Insider Roberts Christopher James

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 295,001 contracts (Direct); Common Shares — 155,382 shares (Direct)

Footnotes (5)

1. F1. Includes 109,564 common shares underlying outstanding restricted share units.
2. F2. The share option is fully vested.
3. F3. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2024.
4. F4. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2025.
5. F5. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 01:09 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Roberts Christopher James

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE SWITZERLAND 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	155,382(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	10/02/2029	Common Shares	7,200	$5.15	D
Share Option (right to buy)	(2)	10/12/2030	Common Shares	7,200	$6.3	D
Share Option (right to buy)	(2)	10/05/2031	Common Shares	7,200	$6.88	D
Share Option (right to buy)	(2)	09/30/2032	Common Shares	7,200	$2.76	D
Share Option (right to buy)	(2)	07/31/2033	Common Shares	29,126	$2.32	D
Share Option (right to buy)	(3)	12/31/2033	Common Shares	55,215	$3.99	D
Share Option (right to buy)	(4)	12/31/2034	Common Shares	92,308	$2.91	D
Share Option (right to buy)	(5)	12/31/2035	Common Shares	89,552	$3.03	D

Explanation of Responses:

1. Includes 109,564 common shares underlying outstanding restricted share units.

2. The share option is fully vested.

3. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2024.

4. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2025.

5. The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Christopher James Roberts	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)